集成化数据分析在生物标志物发现及个性化医疗上具有优势

过去20年基因组的革命提供给医药公司无以数计的潜在药物靶标。创造强有力的新药来作用这些靶标已经迫在眉睫。然而,大多数低挂水果已经被采摘,药物开发因此变得越来越困难。为了获得美国食品药品管理局(FDA)批准,新药必须证明其安全性和有效性,特别是当新药与现存药物进行比较时。

Use of Integrated Data Analysis to Gain an Advantage in Biomarker Discovery and Personalized Medicine

The genomic revolution of the last two decades has provided pharmaceutical companies with an almost overwhelming number of potential drug targets.The creation of potent new drugs addressing those targets is imminent.However,with most of the low-hanging fruit already picked,drug development is becoming an increasingly difficult endeavor.To gain FDA approval,new drugs must demonstrate safety and efficacy,especially when compared to existing drugs.